According to Evofem Biosciences
's latest financial reports the company has N/A in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | N/A | -100% |
2022-12-31 | โน0.22 B | -60.19% |
2021-12-31 | โน0.57 B | -83.91% |
2020-12-31 | โน3.57 B | 110.64% |
2019-12-31 | โน1.69 B | 1725.32% |
2018-12-31 | โน92.99 M | 20.27% |
2017-12-31 | โน77.32 M | -90.09% |
2016-12-31 | โน0.77 B | -68.91% |
2015-12-31 | โน2.50 B | -47.88% |
2014-12-31 | โน4.81 B | 1685.33% |
2013-12-31 | โน0.26 B | -55.64% |
2012-12-31 | โน0.60 B |